<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04979273</url>
  </required_header>
  <id_info>
    <org_study_id>20-02-0130</org_study_id>
    <nct_id>NCT04979273</nct_id>
  </id_info>
  <brief_title>The Role of Hypertonic Dextrose Spray as Endoscopic Topical Hemostatic Agent for Acute Non-Variceal Upper GI Bleeding</brief_title>
  <official_title>The Role of Hypertonic Dextrose Spray as Endoscopic Topical Hemostatic Agent for Acute Non-Variceal Upper Gastrointestinal Bleeding: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr Cipto Mangunkusumo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr Cipto Mangunkusumo General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted to evaluate the effectivity of hypertonic dextrose spray as an&#xD;
      endoscopic topical hemostatic agent, compared to conventional agent (adrenaline injection,&#xD;
      followed by hemoclip or thermocoagulation), in patients with acute non-variceal upper GI&#xD;
      bleeding.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemostatic success</measure>
    <time_frame>5 minute</time_frame>
    <description>Number of participants whose bleeding stops within five minutes after intervention is given. Outcome is assessed by independent assessor (not the endoscopy operator), who also attend the endoscopy session and could observe whether the bleeding stops.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Re-bleeding</measure>
    <time_frame>7 days</time_frame>
    <description>Number of participants who experience decrease in hemoglobin &gt;1g/dl or need additional hemostatic endoscopy within one week after intervention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Gastro Intestinal Bleeding</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients within control group will be given adrenaline 1:20.000 injection, followed by thermocoagulation or hemoclip</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dextrose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients within this group will be given adrenaline 1:20.000 injection, followed by dextrose 40% spray</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextrose 40 % in Water</intervention_name>
    <description>injection of adrenaline 1:20.000, followed by dextrose 40% spray</description>
    <arm_group_label>Dextrose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adrenaline 1 Mg/mL Solution for Injection</intervention_name>
    <description>injection of adrenaline 1:20.000, followed by thermocoagulation or hemoclip</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Dextrose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>argon plasma coagulation</intervention_name>
    <description>Thermocoagulation</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hemoclip</intervention_name>
    <description>Hemoclip</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with acute non-variceal upper gastrointestinal bleeding caused by peptic or&#xD;
             duodenal ulcer, polyps, tumors or malignancy&#xD;
&#xD;
          -  Patients consented to study participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with thrombocytopenia (thrombocyte count &lt;100.000 cells/ul) and other forms&#xD;
             of coagulopathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hasan Maulahela, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dr Cipto Mangunkusumo General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hasan Maulahela, MD</last_name>
    <phone>+6281283602549</phone>
    <email>hasanmaulahela@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dr. Cipto Mangunkusumo General Hospital</name>
      <address>
        <city>Jakarta Pusat</city>
        <state>DKI Jakarta</state>
        <zip>10430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hasan Maulahela, MD</last_name>
      <phone>+6281283602549</phone>
      <email>hasanmaulahela@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 2, 2021</study_first_submitted>
  <study_first_submitted_qc>July 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2021</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dr Cipto Mangunkusumo General Hospital</investigator_affiliation>
    <investigator_full_name>Hasan Maulahela, MD</investigator_full_name>
    <investigator_title>Head of Gastrointestinal Endoscopy Center FKUI-RSCM</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

